• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Faleiro Gitanjali Pinto returned 14,446 shares to the company, closing all direct ownership in the company (SEC Form 4)

    12/1/23 8:47:11 AM ET
    $GHL
    Investment Bankers/Brokers/Service
    Finance
    Get the next $GHL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Faleiro Gitanjali Pinto

    (Last) (First) (Middle)
    C/O GREENHILL & CO., INC.
    1271 AVENUE OF THE AMERICAS

    (Street)
    NEW YORK NY 10020

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GREENHILL & CO INC [ GHL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    11/30/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/30/2023 D 14,446(1)(2) D (1)(2) 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (3) 11/30/2023 D 49,330 (3) (3) Common Stock 49,330 (3) 0 D
    Explanation of Responses:
    1. Reflects the disposition of securities pursuant to the Agreement and Plan of Merger, dated as of May 22, 2023 (the "Merger Agreement"), by and among Greenhill & Co., Inc. a Delaware corporation (the "Company"), Mizuho Americas LLC, a Delaware limited liability company ("Purchaser"), and Blanc Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Purchaser ("Sub"), pursuant to which on November 30, 2023, Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly-owned subsidiary of Purchaser.
    2. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.01 per share, of the Company ("Company Common Stock") (except for shares held by the Company as treasury stock, by any of the Company's subsidiaries, by Purchaser or any of Purchaser's subsidiaries (including Sub), or by any holder who was entitled to demand appraisal and has properly and validly demanded appraisal of such shares of Company Common Stock pursuant to Section 262 of the General Corporation Law of the State of Delaware, which, in each case, was treated as described in the Merger Agreement), was canceled and automatically converted into the right to receive $15.00 in cash (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
    3. At the Effective Time, pursuant to the Merger Agreement, each of the 49,330 outstanding Company restricted stock units held by the Reporting Person was converted into an unvested Purchaser cash-based award with respect to an amount in cash equal to the product obtained by multiplying (a) the Merger Consideration by (b) the number of shares of Company Common Stock covered by such award, which will otherwise remain subject to the same terms and conditions applicable to such award as of immediately prior to the Effective Time.
    /s/ Mark R. Lasky, Attorney-in-Fact for Gitanjali Pinto Faleiro 12/01/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHL

    DatePrice TargetRatingAnalyst
    4/28/2022$16.50 → $12.00Mkt Perform → Underperform
    Keefe Bruyette
    3/9/2022$18.50 → $17.00Neutral
    Piper Sandler
    7/14/2021$15.50Underperform → Market Perform
    Keefe, Bruyette & Woods
    More analyst ratings

    $GHL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Greenhill & Co. Inc.

      15-12G - GREENHILL & CO INC (0001282977) (Filer)

      12/11/23 4:03:05 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form S-8 POS filed by Greenhill & Co. Inc.

      S-8 POS - GREENHILL & CO INC (0001282977) (Filer)

      12/1/23 8:44:25 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form S-8 POS filed by Greenhill & Co. Inc.

      S-8 POS - GREENHILL & CO INC (0001282977) (Filer)

      12/1/23 8:41:52 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Greenhill downgraded by Keefe Bruyette with a new price target

      Keefe Bruyette downgraded Greenhill from Mkt Perform to Underperform and set a new price target of $12.00 from $16.50 previously

      4/28/22 6:12:12 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Piper Sandler reiterated coverage on Greenhill & Co with a new price target

      Piper Sandler reiterated coverage of Greenhill & Co with a rating of Neutral and set a new price target of $17.00 from $18.50 previously

      3/9/22 6:45:52 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co upgraded by Keefe, Bruyette & Woods with a new price target

      Keefe, Bruyette & Woods upgraded Greenhill & Co from Underperform to Market Perform and set a new price target of $15.50

      7/14/21 5:05:57 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Land & Buildings Nominates Two Independent Candidates – Jim Hoffmann and Adam Troso – for Board of National Health Investors

      Believes That Incremental Changes Since Last Annual Meeting Are Insufficient to Address the Poor Corporate Governance and Concerning Conflicts of Interest Threatening to Prevent NHI From Reaching its Full Value Potential Highlights the Urgent Need for NHI to Have Truly Independent Directors With the Right Expertise in the Boardroom Given Ongoing Lease Renewal Negotiations With Major Tenant National Healthcare Corp (NHC) Details Concerns That NHC Lease Negotiations Will Not Reflect Market Value Given Board Member Conflicts; Lease Likely Has 75% Upside Based on Strong Coverage and Precedent Transactions and Could Boost Earnings 13% Or More Believes NHI Shares Have 50% Upside Over the Next

      2/19/25 8:00:00 AM ET
      $DOC
      $GHL
      $HCP
      $ING
      Real Estate Investment Trusts
      Real Estate
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co. Reports Second Quarter 2023 Results

      Announced definitive agreement for Greenhill to be acquired by Mizuho Financial Group, Inc. in an all-cash transaction at $15 per share Quarterly revenues of $71.4 million, up 98% from prior year's second quarter Year to date revenues of $121.1 million, up 49% from the same period in 2022 Compensation ratio of 54% for the quarter; 82% for the year to date period Operating margin of 21% for the quarter Recruited two additional Managing Directors during the quarter Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $71.4 million, net income of $4.4 million and diluted earnings per share of $0.21 for the quarter ended June 30, 2023. The Firm's second quarter

      8/9/23 4:05:00 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13G/A - GREENHILL & CO INC (0001282977) (Subject)

      7/17/23 4:18:36 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13D/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13D/A - GREENHILL & CO INC (0001282977) (Subject)

      5/22/23 5:28:29 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13G/A filed by Greenhill & Co. Inc. (Amendment)

      SC 13G/A - GREENHILL & CO INC (0001282977) (Subject)

      1/9/23 11:41:53 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ferro Kevin returned 81,495 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:08:03 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Wyles David returned 98,707 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:05:56 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Ekman Ulrika returned 10,205 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - GREENHILL & CO INC (0001282977) (Issuer)

      12/1/23 9:03:36 AM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance

    $GHL
    Financials

    Live finance-specific insights

    See more
    • Land & Buildings Nominates Two Independent Candidates – Jim Hoffmann and Adam Troso – for Board of National Health Investors

      Believes That Incremental Changes Since Last Annual Meeting Are Insufficient to Address the Poor Corporate Governance and Concerning Conflicts of Interest Threatening to Prevent NHI From Reaching its Full Value Potential Highlights the Urgent Need for NHI to Have Truly Independent Directors With the Right Expertise in the Boardroom Given Ongoing Lease Renewal Negotiations With Major Tenant National Healthcare Corp (NHC) Details Concerns That NHC Lease Negotiations Will Not Reflect Market Value Given Board Member Conflicts; Lease Likely Has 75% Upside Based on Strong Coverage and Precedent Transactions and Could Boost Earnings 13% Or More Believes NHI Shares Have 50% Upside Over the Next

      2/19/25 8:00:00 AM ET
      $DOC
      $GHL
      $HCP
      $ING
      Real Estate Investment Trusts
      Real Estate
      Investment Bankers/Brokers/Service
      Finance
    • Greenhill & Co. Reports Second Quarter 2023 Results

      Announced definitive agreement for Greenhill to be acquired by Mizuho Financial Group, Inc. in an all-cash transaction at $15 per share Quarterly revenues of $71.4 million, up 98% from prior year's second quarter Year to date revenues of $121.1 million, up 49% from the same period in 2022 Compensation ratio of 54% for the quarter; 82% for the year to date period Operating margin of 21% for the quarter Recruited two additional Managing Directors during the quarter Greenhill & Co., Inc. (NYSE:GHL) today reported revenues of $71.4 million, net income of $4.4 million and diluted earnings per share of $0.21 for the quarter ended June 30, 2023. The Firm's second quarter

      8/9/23 4:05:00 PM ET
      $GHL
      Investment Bankers/Brokers/Service
      Finance
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance